Stereotaxis Inc(STXS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.24 | Insider Own | 23.21% | Shs Outstand | 97.9M | Perf Week | -5.8% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | 27.42% | Insider Trans | - | Shs Float | 76.9M | Perf Month | -10.96% |
| Enterprise Value | 0.13B | PEG | - | EPS next Q | -0.05 | Inst Own | 43.92% | Short Float | 7% | Perf Quarter | -28.18% |
| Income | -0.02B | P/S | 4.33 | EPS this Y | 17.33% | Inst Trans | 0.42% | Short Ratio | 6.45 | Perf Half Y | -32.64% |
| Sales | 0.03B | P/B | 10.4 | EPS next 5Y | - | ROA | -46.14% | Short Interest | 5.38M | Perf YTD | -43.48% |
| Book/sh | 0.13 | P/C | 12.42 | EPS past 3/5Y | 0.82% -17.98% | ROE | -184.27% | 52W High | -63.79% ($3.59) | Perf Year | -53.74% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | 4.78% 3.99% | ROIC | -101.65% | 52W Low | 4.84% ($1.24) | Perf 3Y | -23.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 13.55% | Gross Margin | 55.57% | Volatility(W/M) | 3.98% 5.03% | Perf 5Y | -77.74% |
| Dividend TTM | - | EV/Sales | 4.33 | Sales Y/Y TTM | -5.47% | Oper. Margin | -65.23% | ATR (14) | 0.07 | Perf 10Y | 97.57% |
| Dividend Ex-Date | - | Quick Ratio | 0.94 | EPS Q/Q | -1.49% | Profit Margin | -78.45% | RSI (14) | 36.91 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.41 | Sales Q/Q | -12.82% | SMA20 | -6.61% ($1.39) | Beta | 1.36 | Target Price | $3 |
| Payout | - | Debt/Eq | 0.3 | Earnings | 2026/8/11 | SMA50 | -11.31% ($1.47) | Rel Volume | 0.75 | Prev Close | $1.32 |
| Employees | 131 | LT Debt/Eq | 0.26 | EPS/Sales Surpr. | - -8.14% | SMA200 | -32.89% ($1.94) | Avg Volume(3M) | 0.83M | Price | $1.3 |
| IPO | 2004/8/12 | Option/Short | Yes/Yes | Trades | 2260 | Volume | 625,269 | Change | -1.52% |
Company
STXS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Stereotaxis is a US medical device company that develops robotic navigation systems specialized for cardiac electrophysiology procedures. The company is expanding its presence in the arrhythmia treatment market through its magnetic field-based remote catheter manipulation platform and digital operating room solutions. It carries both the growth potential and the volatility typical of micro-cap stocks.
Over the past 1 year, on the lower side
64% below its 1-year high.
STXS has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -23.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 43.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
IWO 0.00%
VTWG 0.00%
HONG 0.00%
ITWO 0.00%It ranks #4 in the industry
Based on market cap of $130M.
STXS $130M PER -
ISRG $127B PER 41.3
BDX $48B PER 53.2
MDLN $43B PER 38.0
FAQ
What kind of company is STXS?
STXS belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of STXS?
The market cap of STXS is approximately $130M, ranking 4,401 within its sector.
What is the 52-week high and low for STXS?
STXS has recorded a 52-week high of $3.59 and a low of $1.24.
